Sean Maduck Sells 20,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares in the company, valued at $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Corcept Therapeutics Price Performance

NASDAQ CORT traded up $0.81 on Monday, reaching $51.66. The company had a trading volume of 690,876 shares, compared to its average volume of 825,825. The stock has a market capitalization of $5.41 billion, a PE ratio of 41.00 and a beta of 0.56. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $62.22. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $54.63 and its 200 day moving average price is $43.62.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The firm had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The business’s revenue was up 47.7% compared to the same quarter last year. As a group, equities analysts predict that Corcept Therapeutics Incorporated will post 1.35 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CORT. Capital Performance Advisors LLP bought a new position in Corcept Therapeutics during the third quarter valued at $25,000. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Corcept Therapeutics during the 3rd quarter valued at about $36,000. GAMMA Investing LLC lifted its holdings in shares of Corcept Therapeutics by 85.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,147 shares during the last quarter. KBC Group NV grew its position in Corcept Therapeutics by 21.3% in the third quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 496 shares in the last quarter. Finally, Quest Partners LLC raised its position in Corcept Therapeutics by 23.2% during the second quarter. Quest Partners LLC now owns 5,266 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 992 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CORT shares. Truist Financial boosted their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Piper Sandler increased their price objective on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 18th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.